Solid Start Act of 2021 This bill permanently authorizes and expands the Solid Start program, which is an outreach program for veterans in their first year of separation from the military. Specifically, the bill requires the Department of Veterans Affairs (VA) to coordinate with the Department of Defense to collect updated contact information during transition classes or separation counseling for members of the Armed Forces who are separating from service; explain the existence and purpose of the program; call veterans three times within the first year of separation; publish information about the program in booklets and on the VA website; provide women veterans with information tailored to their health care and benefit needs; provide information on access to state and local resources, such as Vet Centers; gather and analyze data that assesses the effectiveness of the program; ensure calls are tailored to each veteran's needs by conducting quality assurance tests; and prioritize outreach to veterans who have accessed mental health resources prior to separation from the Armed Forces. Under the bill, the VA is authorized to (1) encourage members of the Armed Forces to provide additional contact information if they are unreachable following their separation, (2) follow up on missed phone calls, and (3) reach out to veterans who separated prior to the initiation of the Solid Start program.
This resolution expresses support for the designation of National Vitiligo Awareness Day. (Vitiligo is a chronic condition that results in the loss of pigment in patches on the skin, hair, eyes, and inside of the mouth; the condition may lead to discomfort, itching, and pain.)
Lead Poisoning Prevention Act of 2021 This bill reauthorizes through FY2026 grants and programs carried out by the Centers for Disease Control and Prevention for screening and other public health activities to prevent childhood lead poisoning. Additionally, the bill changes the name of an advisory body that coordinates federal lead poisoning prevention efforts from the Interagency Task Force on the Prevention of Lead Poisoning to the Advisory Committee on Childhood Lead Poisoning Prevention. It also modifies the committee's membership, reporting requirements, and other duties.
Urban Waters Federal Partnership Act of 2021 This bill provides statutory authority for the Urban Waters Federal Partnership Program. Under the program, the Environmental Protection Agency and other specified agencies must reconnect urban communities, particularly urban communities that are overburdened or economically distressed, with their waterways by improving coordination among federal agencies.
HR 5553 prohibits the Secretary of Veterans Affairs from providing or paying for surgical treatments related to gender transition. This directly affects transgender veterans who rely on VA healthcare for gender-affirming surgical procedures. The bill blocks VA funding specifically for these surgical treatments, without altering coverage for other healthcare services. It applies to all veterans seeking such care through the VA system.
Cosmetic Supply Chain Transparency Act of 2021 This bill requires the Food and Drug Administration (FDA) to maintain a list of certain nonfunctional constituents in cosmetics that are harmful to human health or the environment, authorizes the FDA to request from a brand owner (i.e., the entity bringing a cosmetic to market) certain information about a cosmetic's ingredients, and addresses related issues. For each listed nonfunctional constituent, the list must identify the ingredient or cosmetic (or category of ingredient or cosmetic) in which the constituent is known or reasonably expected to be present. The FDA must also (1) establish procedures for petitions to add substances to the list, (2) issue guidance for industry related to testing and detecting such nonfunctional constituents, and (3) establish a committee to provide advice on creating the list and developing the required industry guidance. Within a year of a nonfunctional constituent being added to the list, a supplier of an ingredient or cosmetic must test for that constituent and provide a brand owner the results and other information before selling the ingredient or cosmetic to the brand owner. A supplier of an ingredient or cosmetic must provide additional information about the item upon a brand owner's request. Brand owners must maintain records with information about the suppliers of ingredients and raw materials used in their cosmetics and provide such information to the FDA upon request. The bill also imposes civil penalties for brand owners and suppliers that violate this bill's provisions.
Accountability in Foreign Animal Research Act This bill prohibits the National Institutes of Health from conducting or supporting research that involves testing on vertebrate animals in China, Cuba, Iran, North Korea, Russia, or other countries determined to be a foreign adversary.
HR 5537, the Toxic-Free Beauty Act of 2021, bans specific chemicals in cosmetics under federal law. It prohibits the use of substances like certain PFAS (water-repellent chemicals), phthalates (e.g., dibutyl phthalate), formaldehyde, mercury, and specific parabens in cosmetic products. The ban directly affects cosmetic manufacturers, requiring them to reformulate products, and benefits consumers by removing these chemicals from beauty items. The law takes effect on January 1, 2025, with the ban applying to products bearing or containing the listed substances.
Cosmetic Fragrance and Flavor Ingredient Right to Know Act of 2021 This bill imposes disclosure and labeling requirements on cosmetics products that contain certain ingredients. A cosmetics product that fails to meet such requirements may not be sold. Within two years of this bill's enactment, a cosmetics product's labeling or packaging must indicate the use of any ingredient that (1) is identified on specified lists of harmful or potentially harmful chemicals, such as chemicals identified as carcinogenic to humans by the Environmental Protection Agency or toxic air contaminants under California regulations; or (2) must be disclosed under certain European Union laws and is present in a product above specified concentrations. The Food and Drug Administration must publish and periodically update on its website a list of the ingredients subject to this requirement. Within one year of this bill's enactment, a brand owner (i.e., the entity bringing a cosmetics product to market) must disclose certain information on its website if a cosmetics product contains any fragrance or flavor ingredient that is (1) present in the product above a certain concentration, or (2) subject to this bill's labeling or packaging requirement. The website must disclose the use of the ingredient in question and other information, such as the ingredient's functional purpose. The use of an ingredient subject to this bill's requirements shall not be treated as a confidential trade secret, but the concentration of such an ingredient shall be treated as confidential commercial information.
Cosmetic Safety for Communities of Color and Professional Salon Workers Act of 2021 This bill imposes labeling requirements on cosmetics intended for professional use, requires research on health issues relating to cosmetics, and addresses related issues. The Food and Drug Administration (FDA) must require (1) the labeling for cosmetics intended for professional use to include the name of each ingredient in descending order of predominance; and (2) the manufacturer, distributor, or seller of such a cosmetic to provide this information on its website. The Occupational Safety and Health Administration must issue a standard requiring each manufacturer or importer selling a cosmetic intended for professional use to (1) obtain or develop a safety data sheet for the cosmetic in various languages; and (2) make the data sheet available to relevant distributors and employers, such as hair salon owners. The standard must also require employers to make the data sheet available to employees exposed to the product and provide to employees versions of the sheet in languages other than English upon request. The FDA must conduct (or award grants for) research into chemicals linked to adverse health effects and most commonly found in cosmetics that are (1) marketed to women and girls of color; or (2) used by professional nail, hair, and beauty salon workers. The FDA must also award grants to support research focused on designing safer cosmetic chemicals, such as those with no inherent toxicity. The FDA must take actions to ensure that cosmetics marketed to women and girls of color are in full compliance with FDA requirements.
Choose Home Care Act of 2021 This bill provides for coverage of home-based extended care services under Medicare. Specifically, the bill provides for coverage of services that are furnished to Medicare beneficiaries in their homes by home health agencies, including nursing care, meals and nutritional support, home medical supplies, nonemergency medical transportation, and care coordination. Coverage includes 30 days of post-hospital care and other periods of extended illness, as determined by the Centers for Medicare & Medicaid Services (CMS). Home health agencies that provide such services may receive additional payments in accordance with a specified methodology. The CMS may make payments for covered services furnished before 2022 during any period in which there is a public health emergency.
Stabilizing Medicare Access to Rehabilitation and Therapy Act or the SMART Act This bill modifies the application of a certain Medicare payment methodology for outpatient physical therapy services and outpatient occupational therapy services that are furnished by a therapy assistant. Under current law, effective January 1, 2022, payment for such services is 85% of the otherwise applicable rate. The bill delays this effective date by one year and excludes services that are furnished in rural or medically underserved areas from this payment methodology. The bill also specifies that supervision requirements for outpatient physical therapy services that are furnished through private practice may not be more stringent for purposes of Medicare coverage than under state law.
